

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica

Table SI. SNPs sequence of the IL 17RA, TNF α promoter region and TRAF3 genes

SNP	Context sequence [VIC/FAM]	
rs4819554	GGGAAGTAACGACTCTCTTAGGTGC	[A/G]
(IL17RA)	GCTGGGACACAGTCTCACAGACCAG	
rs361525	GGCCCAGAAGACCCCCCTCGGAATC	[A/G]
(TNF α)	GAGCAGGGAGGATGGGGAGTGTGAG	
rs33980500	TGACTTGGGTATGGTTCTGATTCAT	[C/T]
(TRAF3)	AACCTCCACAGGAATGCTTCGGTTC	

Table SII. IL-17RA, TNF α and TRAF3 genotype and allele frequencies in mild and moderate/severe psoriasis patients and grouped by age onset of the disease.

SNP	Genotype Allele	Mild Psoriasis	Moderate Severe Psoriasis	X ² Mid or Fisher	P	OR	>29 years	<30 years	X ² Mid o r Fisher	P	OR
rs4819554 (IL17RA)	AA	12 (54.5%)	65 (68.4%)	2.30	0.116		39 (68.4%)	38 (63.4%)	2.60	0.272	
	AG	9 (40.9%)	25 (26.3%)				17 (29.8%)	17 (28.3%)			
	GG	1 (4.5%)	5 (5.3%)				1 (1.8%)	5 (8.3%)			
	A	33 (75.0%)	155 (81.58%)	0.97	0.165	0.67 (0.31-1.47)	93 (77.5%)	95 (83.3%)	1.26	0.134	0.69 (0.36-1.32)
	G	11 (25.0%)	35 (18.42%)				27 (22.5%)	19 (16.7%)			
rs361525 (TNFα promoter region)	GG	21 (91.3%)	82 (83.7%)	2.11	0.348		0 (0%)	1 (1.5%)	3.25	0.197	
	AG	2 (8.7%)	15 (15.3%)				11 (19.3%)	6 (9.4%)			
	AA	0 (0%)	1 (1.0%)				46 (80.7%)	57 (89.1%)			
	G	44 (95,6%)	179 (91.3%)	0.96	0.175	0.47 (0.10-2.14)	120 (93.7%)	103 (90.4%)	0.96	0.166	0.62 (0.24-1.61)
	A	2 (4,4%)	17 (8.7%)				8 (6.3%)	11 (9.6%)			
rs33980500 (TRAF3)	CC	17 (73.9%)	71 (75.5%)	1.09	0.578		46 (75.4%)	42 (75.0%)	2.30	0.316	
	CT	6 (26.1%)	21 (22.3%)				15 (24.6%)	12 (21.4%)			
	TT	0 (0%)	2 (2.2%)				0 (0%)	2 (3.6%)			
	C	40 (87.0%)	163 (86.7%)	0.01	0.495	1.02 (0.39-2.65)	107 (87.7%)	96 (85.7%)	0.20	0.33	1.19 (0.56-2.53)
	T	6 (13.0%)	25 (13.3%)				15 (12.3%)	16 (14.3%)			

The value of p less than 0.05 was considered statistically significant. Patients were recruited from the Dermatology Outpatient Clinics of Pedro Ernesto University Hospital (HUPE) or Piquet Carneiro University Polyclinic (PPC), with selection criteria including a disease duration of more than 10 years and the absence of psychiatric disorders or intellectual impairments. Clinical severity was assessed using the Psoriasis Area and Severity Index (PASI), patients undergoing systemic therapy or phototherapy were classified within the severe group.